United Therapeutics Sustainability Profile
United Therapeutics Corporation, commonly referred to as United Therapeutics, is a pioneering biotechnology company headquartered in the United States. Founded in 1996, the company has established itself as a leader in the development of innovative therapies for patients with chronic and life-threatening conditions, particularly in the field of pulmonary arterial hypertension (PAH). With a strong operational presence across North America and Europe, United Therapeutics focuses on creating unique, life-saving products, including its flagship medications like Remodulin and Tyvaso. These therapies are distinguished by their advanced delivery systems and commitment to improving patient quality of life. Recognised for its significant contributions to the biopharmaceutical industry, United Therapeutics has achieved notable milestones, including the successful development of organ preservation technologies. The company continues to solidify its market position through ongoing research and a dedication to addressing unmet medical needs.
DitchCarbon Score
How does United Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
United Therapeutics's score of 31 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
United Therapeutics's reported carbon emissions
United Therapeutics, headquartered in the US, has set ambitious climate commitments aimed at significantly reducing its carbon emissions. Although specific emissions data for the most recent year is not available, the company has established clear reduction targets for its Scope 1 and Scope 2 emissions. By 2030, United Therapeutics aims to reduce its Scope 1 emissions by 30% from 2020 levels. Additionally, the company has committed to a similar 30% reduction in its Scope 2 emissions over the same timeframe. Furthermore, United Therapeutics has set a near-term goal to reduce its Scope 1 and Scope 2 emissions to near zero by the middle of this decade, specifically targeting the years 2023 to 2025. These initiatives reflect United Therapeutics's commitment to addressing climate change and aligning with industry standards for sustainability. The company's proactive approach demonstrates its dedication to reducing its environmental impact and contributing to a more sustainable future.
How Carbon Intensive is United Therapeutics's Industry?
How Carbon Intensive is United Therapeutics's Location?
United Therapeutics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
United Therapeutics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
